Tracer library / [177Lu]Lu-DOTA-GA13

[177Lu]Lu-DOTA-GA13

Also written as [Lu-177]Lu-DOTA-GA13

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Neuroendocrine neoplasms Preclinical only, no clinical indication yet Other radioligand therapy

What it is

Compound class: DOTA-conjugated gastramide peptide (CCK2R-targeting analogue)
Target / mechanism: Cholecystokinin-2 receptor (CCK2R) PMID 41509636
Clinical application: Neuroendocrine tumors PMID 41509636
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	—	≥99%	DOTA-GA13	41509636 2026 RSC Adv These DOTA-peptides were subsequently radiolabeled with 177Lu as detailed in the SI materials.

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-GA13, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41509636. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41509636: 'DOTA-GA4, DOTA-GA13, and the clinical standard CP04 were synthesized and radiolabeled with lutetium-177 (177Lu)'.